AB-CHFUPYCA

AB-CHFUPYCA is a compound of the cannabinoid family, and is a homolog of FUB-APINACA, but differs in that the indazole ring has been replaced by an indole ring. It was first identified in Japan in 2015. Although its pharmacology is not yet fully understood, it is believed to act as a full agonist at the CB1 receptor, which is responsible for its psychoactive effects.

Etymology

The name "AB-CHFUPYCA" is an acronym derived from its chemical structure: AminoBenzyl-CycloHexylmethyl-Furan-UndecaPhenyl-YlCarboxylAte.

Pharmacology

AB-CHFUPYCA is believed to act as a full agonist at the CB1 receptor, which is found primarily in the brain. This receptor is a member of the G protein-coupled receptor family and is one of the most abundant neurotransmitter receptors in the brain. Activation of the CB1 receptor produces psychoactive effects, which are thought to be responsible for the euphoria and relaxation often associated with cannabis use.

Legal Status

In the United States, AB-CHFUPYCA is a Schedule I controlled substance. This means it has a high potential for abuse and no accepted medical use. In the United Kingdom, it is a Class B drug under the Misuse of Drugs Act 1971, which means it is illegal to possess, distribute, or manufacture.

See Also

• Cannabinoid
• FUB-APINACA
• Indazole
• Indole
• CB1 receptor
• G protein-coupled receptor
• Cannabis

AB-CHFUPYCA Resources
Latest articles Most recent articles Ongoing trials	Wikipedia